Micky

110 posts

Micky banner
Micky

Micky

@MMick1222347

Meh

Katılım Haziran 2023
66 Takip Edilen0 Takipçiler
Mary B Schanck
Mary B Schanck@MaryBschanck·
$TGTX 71 days left before the bonus window closes. Needs a $10B valuation for 60 of those days to hit, unless a buyout happens which would also satisfy it. Given the ego and the fact this target was set 5 years ago, you know Michael’s going to push hard to get it as close as possible.
English
2
2
7
960
Micky
Micky@MMick1222347·
@jacked2thatits @zipjet @EL_Goeffrey With all these buybacks, I have not seen the outstanding share count go down. In fact, I just noticed it went UP from 158.8M to 159.7M some time in the last week or two. Any idea why? They immediately giving out bought back shares as options to employees? $tgtx
English
1
0
3
375
zipjet
zipjet@zipjet·
$TGTX $300M buyback $262M remaining. FINANCING & CAPITAL STRUCTURE New 5-year $750M senior secured credit facility with Blue Owl Capital Repays existing $250M facility Net new capital raised: $500M (non-dilutive) Option to expand facility by additional $250M Total potential facility size: $1B SHARE REPURCHASE PROGRAM Increased buyback authorization from $100M to $300M Already repurchased $38M of stock Average repurchase price: $28.98 per share Signals confidence in valuation and willingness to deploy capital USE OF CAPITAL Share repurchases Business development / acquisitions Operational initiatives Supported by a cash-flow positive business MANAGEMENT TAKEAWAYS CEO Michael Weiss highlighted: Improved scale and terms vs prior facility Ability to fund growth of BRIUMVI and pipeline Buyback reflects confidence in long-term value Blue Owl noted: Strong commercial execution of BRIUMVI Disciplined growth strategy BRIUMVI OVERVIEW Anti-CD20 monoclonal antibody for relapsing multiple sclerosis (RMS) Glycoengineered for efficient B-cell depletion Approved in U.S. and multiple international markets KEY SAFETY POINTS Infusion reactions (~48%) Infection rate ~56% (serious ~5%) Risk of HBV reactivation Risk of PML (rare but severe brain infection) Other risks: liver injury, reduced immunoglobulins, fetal risk INVESTOR TAKEAWAY Large non-dilutive financing strengthens balance sheet Significant expansion of buybacks suggests management sees undervaluation Provides flexibility for growth, M&A, and pipeline investment Reinforces confidence in BRIUMVI-driven cash flow
English
3
4
10
1.1K
Micky
Micky@MMick1222347·
@kylegriffin1 War is not a video game. Actual innocent people are getting killed. This is sick.
English
0
0
1
55
Micky
Micky@MMick1222347·
@cturnbull1968 I don’t see what any prior president has to do with today. Blame them or not, we know these files have some fucked up shit in them. The Trump admin needs to release them all, now. You’d think he’d relish in the adoration from righting this wrong, unless he’s a major perpetrator.
English
0
0
1
30
Micky
Micky@MMick1222347·
@Lucy3370 I’m baffled. $tgtx are printing money in growth phase with a p/e under 10. This should be trading closer to how $exel does with one blockbuster and an early phase pipeline (p/e around 18). Makes no sense for them to be this cheap. It’s very frustrating.
English
0
1
12
647
R
R@Lucy3370·
$tgtx wow consistantly weaker than $xbi , yet stellar fundamentals. Almost trades like crypto. Expect SP to turn quite a bit once we get PK data (by mid-year)
English
2
0
7
803
Micky
Micky@MMick1222347·
@Lucy3370 It’s at essentially the same level it was right before JPM last year for what it’s worth $tgtx.
English
0
0
2
535
R
R@Lucy3370·
$tgtx spoke w/few folks. Nobody knows anything. there r some that have trimmed but had large positions. We will find out AH Tuesday if shares were stolen or someone had neg news b4 every1 else. Anything now is a guess -done this rodeo b4-not fun but not necessarily reason to sell
R@Lucy3370

@Paperboy2009 $tgtx no idea what’s going on? Dont expect any bad news at #jpm26 but if anything neg there, I wud say some “privileged folks” had info b4 retail. I will reserve judgement till then- non-stop selling really sucks but not much u can do. Jpm around the corner

English
3
0
14
2.4K
Micky
Micky@MMick1222347·
$tgtx buying Feb calls today. Expecting great guidance at JPM. Wouldn’t be surprised if we have $300-400m in buybacks next year. $950+ in rev, ~$500 in earnings. This ramps significantly over the next year.
English
1
0
8
430
Micky
Micky@MMick1222347·
@Lucy3370 I’m kinda hoping it dips a bit more or at least holds here to end of year. I’m hoping to pick up a bunch of Feb $32 calls for under $2.
English
0
0
1
55
R
R@Lucy3370·
$tgtx end of tax loss selling can’t get here soon enough
English
1
0
4
614
Liam Nissan™
Liam Nissan™@theliamnissan·
J.D. Vance will be president when I win an Oscar
English
348
234
4.8K
69.9K
Micky
Micky@MMick1222347·
@Biohazard3737 Made me think of this. I can’t imagine wanting this level of subservience. It’s pathetic.
Micky tweet media
English
0
0
0
116
Liam Nissan™
Liam Nissan™@theliamnissan·
"Christians" my cold hard Japanese ass
English
65
57
1.2K
20K
Liam Nissan™
Liam Nissan™@theliamnissan·
Right now the "For You" section of Twitter is nothing but right wing assholes listing all the reasons they think SNAP recipients should starve to death
English
1.5K
1.8K
12.6K
197.2K
Micky
Micky@MMick1222347·
@semodough What is the risk of non-adherence with chronic therapies in these patient populations? $NTLA
English
0
0
0
46
Micky
Micky@MMick1222347·
@semodough Might be a stupid question, but with 450 patients dosed and 1 Hy’s Law case, but a couple other serious AE’s representing <1% of the treated pop. Then 10% of that <1% at mortal risk, would you still think there would be patient interest? $NTLA
English
3
0
0
251
Science girl
Science girl@sciencegirl·
Removing a giant hornet's nest
English
78
63
486
70.4K
Micky
Micky@MMick1222347·
@semodough If that deal didn’t happen they’d have been bankrupt by EOY. Good for them for keeping the lights on, but Greg is still a shit CEO and shouldn’t be trusted imo.
English
0
0
0
18
dough
dough@semodough·
$XBI #Biotechs - good deal for $OMER & once again shows improving sentiment for BIOTECHS - OMER was one Biotech imho that was operating at position of weakness - much better Biotechs with better assets out there imho for better deals soon
dough@semodough

$NVO $OMER 340 million upfront Omeros Corporation - Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906) investor.omeros.com/news-releases/…

English
3
1
11
5.5K
Micky
Micky@MMick1222347·
@theliamnissan For your sake, I hope they don’t have access to a tow truck.
English
0
0
0
27
Liam Nissan™
Liam Nissan™@theliamnissan·
This is Trump's most-trusted advisor, folks
English
125
312
2.2K
44K
Micky
Micky@MMick1222347·
@roywoodjr You need to come to New England!
English
0
0
6
81
Micky
Micky@MMick1222347·
@zipjet Make you think they were buying the dip? $tgtx
English
0
0
2
90